The achieved allicin solution was dried with freeze drier and the resulting allicin powder was used for all experiments
Further research is needed to address these gaps and improve care strategies Disclosure of interest: Jose Luis Cambron-Jimenez: Nothing to disclose E-Posters - RISK FACTORS - PRIMARY AND SECONDAR PREVENTION 05.00 - RISK FACTORS AND PREVENTION (PRIMARY AND SECONDARY) - 05.03 - EPIDEMIOLOGY & RISK FACTORS P2513 - ESOC25-1180 PREDICTIVE FACTORS OF UNFAVORABLE OUTCOMES AMONG MINOR ISCHEMIC STROKE PATIENTS WITH EARLY NEUROLOGICAL DETERIORATION: DATA FROM A STROKE CENTER IN VIETNAM Dung Nguyentien 1,2,3 , Duy-Ton Mai 1,3 , Phuong Dao 1,3 , Tho Pham-Quang 1 , Tuan Anh Le 1 , Quan Phan-Ha 1 , Trung Vuong-Xuan 1 , Minh Anh Nguyen 1 , Hieu Dinh Trung 1 , Bui Quoc Viet 1 , Tho Phung 1 , Trinh Nguyen Thi Tuyet 1 , Linh Nguyen Thi Thuy 1 , Dung Pham 1 , Hoa Truong 3 1 Stroke Center of Bachmai Hospital, Hanoi, Viet Nam, 2 Hanoi Medical University, Hanoi, Viet Nam, 3 VNU University of Medicine and Pharmacy, 144 Xuan Thuy Street, Cau Giay District, Hanoi, Viet Nam Background and Aims: Minor strokes account for a large proportion of the ischemic stroke population
Rasch LA, Bultink IEM, van Tuyl LHD, Lems WF
The same Harding-lab science gave rise to a clinical drug candidate, fosgonimeton, also called ATH-1017, developed by a company called Athira Pharma
